Health Law Experts in July 24 The New England Journal of Medicine say consumers will be spending a lot of money on these products, and venture capital is flying into the industry.
Smart phones and mobile devices are on the cusp of revolutionizing health care, armed with mobile health apps capable of providing everything from cardiac measurements to sonograms.
While tremendous potential exists to broaden access to medical treatment and control costs with mHealth apps, as they’re called, several health law experts say in a just-published report in The New England Journal of Medicine that more oversight is needed by the U.S. Food and Drug Administration to ensure consumer confidence and safety.
Out of some 100,000 mHealth apps on the market, only about 100 have been cleared by the FDA. Opponents to tighter regulation see the FDA as a deterrent to innovation — and profits.
Book a live interview
 To book a live or taped interview with Nathan Cortez in the SMU News Broadcast Studio call the SMU News office at 214-768-7650 or email news@smu.edu. |
Related links
- New England Journal of Medicine, citation: “FDA Regulation of Mobile Health Technologies“
- The New England Journal of Medicine, full article: “FDA Regulation of Mobile Health Technologies“
- Nathan Cortez
- Nathan Cortez research
- Dedman School of Law
More SMU Research news
Help wanted: Principals who embrace change in wake of Race to the Top
Observed by Texas telescope: Light from huge explosion 12 billion years ago reaches Earth
Low IQ students learn to read at 1st-grade level after persistent, intensive instruction
Richest marine reptile fossil bed along Africa’s South Atlantic coast is dated at 71.5 mya
Satellite view of volcanoes finds the link between ground deformation and eruption“Consumers will be spending a lot of money on these products, and venture capital is flying into the industry,” says the article’s lead author, SMU Dedman School of Law Associate Dean of Research Nathan Cortez, adding that by 2017 mHealth apps are expected to earn $26 billion — up from $2.4 billion in 2013.
The FDA needs “additional funding and in-house technical expertise to oversee the ongoing flood of mHealth products,” the authors note. An under-regulated mobile health industry could create “a Wild West” market, says Cortez, who has conducted extensive research into FDA regulation of mobile health technologies.
“Most consumers take mobile health app claims at face value, and think that because they’re available through a trusted retailer like the iTunes Store, they must have been reviewed by the FDA, which isn’t usually the case,” Cortez says.
Some apps make promises they can’t fulfill, and others make errors that could harm patients
Cortez, who also serves as an associate professor in SMU’s Dedman School of Law, co-wrote the article with Harvard Law School Professor I. Glenn Cohen, faculty director of the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, and author of Human Subjects Research Regulation: Perspectives on the Future (MIT Press, 2014) and Aaron S. Kesselheim, associate professor of medicine at Brigham and Women’s Hospital/Harvard Medical School.
“Although the vast majority of mHealth products are very low-risk, some apps make promises they can’t fulfill, and others make errors that could harm patients,” Cortez notes, pointing out that life-threatening technical mistakes are not only possible – they also have occurred.
One of several examples cited in the study includes Sanofi Aventis’ 2012 recall of a diabetes app that miscalculated insulin dosages.
Several Congressional bills have been proposed to strengthen FDA jurisdiction over mHealth products, with one proposing the creation of a new Office of Wireless Health Technology within the administration, the article notes. Meanwhile, more restrictive bills also have been introduced to keep the FDA from regulating “clinical software” or “applying a complex regulatory framework [that] could inhibit future growth and innovation in this promising market.”
“The conventional wisdom is that FDA regulation will stifle innovation, and that’s a very short-term way to think about this,” Cortez says. “Most Silicon Valley firms aren’t used to much federal regulation, and Internet technologies have been subject to very little federal oversight.”
If dangerous errors and disproven product benefits are allowed to proliferate, “some very useful products will be undermined by widespread consumer distrust,” Cortez contends.
“We’re trying to push lawmakers to empower the FDA, not hamstring it,” he says. “Clarity will help the industry create products more helpful than harmful.” — Denise Gee
Follow SMUResearch.com on twitter at @smuresearch.
SMU is a nationally ranked private university in Dallas founded 100 years ago. Today, SMU enrolls nearly 11,000 students who benefit from the academic opportunities and international reach of seven degree-granting schools. For more information see www.smu.edu.
SMU Dedman School of Law was founded in 1925 and enjoys a national and international reputation of distinction, with graduates who have distinguished themselves as global leaders in law, business and government, and as prominent members of the judiciary.
SMU has an uplink facility located on campus for live TV, radio, or online interviews. To speak with an SMU expert or book an SMU guest in the studio, call SMU News & Communications at 214-768-7650.
